Canagliflozin
Brand name: Invokana
Rank #215 of 500 drugs by total cost
$63.7M
Total Cost
66,550
Total Claims
$63.7M
Total Cost
3,505
Prescribers
$956
Cost per Claim
2,006
Beneficiaries
107,093
30-Day Fills
$18K
Avg Cost/Provider
19
Avg Claims/Provider
About Canagliflozin
Canagliflozin (sold as Invokana) was prescribed 66,550 times by 3,505 Medicare Part D providers in 2023, costing the program $63.7M. At $956 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 212 | Netarsudil Mesylate (Rhopressa) | $65.6M | 129,116 |
| 213 | Risperidone Microspheres (Risperdal Consta) | $64.8M | 47,567 |
| 214 | Venlafaxine Hcl (Venlafaxine Hcl) | $64.7M | 2,187,710 |
| 215 | Canagliflozin (Invokana) | $63.7M | 66,550 |
| 216 | Belimumab (Benlysta) | $63.4M | 13,386 |
| 217 | Collagenase Clostridium Hist. (Santyl) | $63.3M | 70,641 |
| 218 | Insulin Lispro Protamin/Lispro (Humalog Mix 75-25 Kwikpen) | $62.8M | 60,873 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology